Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In writing about reason and common sense, in his Life of reason, George Santayana observed that “those who cannot remember the past are condemned to repeat it”. Regrettably, this aphorism is true of clinical trials in myasthenia gravis (MG). Yoshikawa and colleagues1 report the results of a randomised, double blind, placebo controlled trial of tacrolimus in patients with MG (see page 970). Ironically, the authors cite as models for their protocol two recent trials that similarly failed to show efficacy of mycophenolate mofetil in MG, and probably for the same reasons.
This was a 28 week study in which patients with MG who were in minimal manifestation status (authors' definition) on prednisone 10–20 mg/day were randomised to receive either placebo or tacrolimus 3 mg/day. Prednisone dose was gradually tapered beginning at week 4; the primary outcome measure was …
Competing interests MB was a consultant to Bayhill and Cytokinetics on drug development for myasthenia gravis. DS was a consultant to Bayhill Therapeutics, Cytokinetics and GSK on drug development for myasthenia gravis.
Provenance and peer review Commissioned; not externally peer reviewed.